Results 41 to 50 of about 11,483 (163)

The association between Healthy Eating Index‐2020 and epilepsy: Insights based on NHANES from 2013 to 2018

Epileptic Disorders, EarlyView.
Abstract Background Epilepsy is a serious chronic brain disease. However, limited study is focused on the association between dietary pattern and epilepsy management. Hence, we aim to investigate the association between the Healthy Eating Index (HEI‐2020) and epilepsy odds.
Kun Yu, Yingxin Wang, Huaiqing Gao
wiley   +1 more source

Efficacy of fenfluramine in a pediatric epilepsy patient with a pathogenic SV2A variant: A case report

Epileptic Disorders, EarlyView.
Abstract Pathogenic SV2A gene variants have been reported as causes of epilepsy and are often associated with drug resistance and susceptibility to fever‐related seizures. No highly effective treatments have been established for this condition. We report a female patient with a family history of epilepsy who developed generalized seizures associated ...
Takayuki Mori, Hiroshi Terashima, Yu kakimoto, Mitsuhiro Kato, Shumpei Uchino   +4 more
wiley   +1 more source

Vagus nerve stimulation in super-refractory status epilepticus following hypoxic brain injury: a case report and review of the literature

Interdisciplinary Neurosurgery
Background: Status epilepticus (SE) is a life-threatening neurological condition that can be resistant to pharmacological treatments, particularly when triggered by severe brain insults such as asphyxia.
Farzan Fahim, Mahdi Mehmandoost, Faezeh Mousavinia, Amirmohammad Bahri, Negin Safari Dehnavi, Almirabbas Rouholamini, Omidreza Nikbakhtamirabad, Parisa Nikbakhtamirabad, Diba Akbarzadeh, Sayeh Oveisi, Yousef Moghadasi, Alireza Zali, Bijan Herfedoustbiazar   +12 more
doaj   +1 more source

Super-Refractory Status Epilepticus: A Therapeutic Challenge in Paediatrics [PDF]

Journal of Clinical and Diagnostic Research, 2017
A status epilepticus which persists for 24 hours or more after starting treatment with anaesthesia or has recurred inspite of general anaesthesia is known as Super-Refractory Status Epilepticus (SRSE).
SHRIKIRAN AROOR, KANAPARTHI SHRAVAN, SUNEEL C MUNDKUR, C JAYAKRISHNAN, SAI SRIPAD RAO   +4 more
doaj   +1 more source

Electroclinical phenotypes—genetic characterization of developmental and epileptic encephalopathies in a cohort study

Epileptic Disorders, EarlyView.
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are characterized by refractory seizures and frequently recurring epileptic activity with neurodevelopmental delay or regression that usually begin in early life. We aimed to define the relationship between electroclinical features and etiology, as well as the genotype–phenotype ...
Burcu Yaman, Fulya Kurekci, Sinan Akbas, Ceyda Oney, Mehmet Akif Kilic, Hulya Maras Genc, Ayca Dilruba Aslanger, Edibe Pembegul Yildiz   +7 more
wiley   +1 more source

Treatment of Status Epilepticus [PDF]

Journal of Neurocritical Care, 2016
Status epilepticus is a severe neurological disease associated with substantial mortality and health-care cost. Treatment of status epilepticus should proceed without delay even in the pre-hospital setting because prolonged generalized convulsive ...
Gha-Hyun Lee, Dae Soo Jung
doaj   +1 more source

Intravenous ganaxolone in pediatric super-refractory status epilepticus: A single hospital experience

Epilepsy & Behavior Reports, 2022
Synaptic GABAA receptor (GABAAR) internalization contributes to the drug resistant nature of super-refractory status epilepticus (SRSE). Ganaxolone is a 3β-methylated synthetic analog of the endogenous neuroactive steroid, allopregnanolone, that has ...
Rani K. Singh, Rajdeep Singh, Alejandra Stewart, Katherine Van Poppel, Sarah Klinger, Joseph Hulihan, Heather Van Heusen, Henrikas Vaitkevicius, Maciej Gasior   +8 more
doaj   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse

Epilepsia, EarlyView.
Abstract Epilepsy is a heterogeneous neurological disorder affecting more than 70 million people worldwide, posing significant challenges for clinicians due to its complex etiology, diverse manifestations, variable treatment responses, and the inability to predict seizures or disease onset reliably.
Mirte Scheper, Zining Liu, Aristea S. Galanopoulou, Gernot Hlauschek, Benjamin Sinclair, Wai Lam Leung, Stefanie Dedeurwaerdere, Elisabeth Doran, Solomon L. Moshé, David C. Henshall, Ozlem Akman, Pablo M. Casillas‐Espinosa   +11 more
wiley   +1 more source